Mena FN9h
Kymera Therapeutics Presents Preclinical Data For KT-621, A Potent, Selective, First-In-Class, Oral STAT6 Degrader At The EADV Congress
KT-621 has the potential to provide dupilumab-like activity with an oral small molecule profile for TH2 driven allergic and atopic disease KT-621 demonstrated strong degradation of STAT6 in human ...
FierceBiotech7h
Amgen reports first phase 3 win for $400M eczema drug, but Dupixent rivalry doubts remain
Amgen has shared (PDF) the first phase 3 data on its $400 million eczema drug, linking the | Amgen has shared the first phase ...
Survivors of sex abuse at Illinois juvenile detention facilities hope for justice
Overall, 667 people have alleged they were sexually abused as children at youth facilities in Illinois through lawsuits filed ...
CNBC20h
6% APY savings accounts are here — this is what you need to know
While a 5% annual percentage yield (APY) seems to be the highest offered among savings accounts with no minimums, caps, fees or membership required, some offer 6% APY if you don't mind the ...
rmdopen.bmj22h
Genes deregulated in giant cell arteritis by Nanostring nCounter gene expression profiling in temporal artery biopsies
The data were normalised for the RNA content selecting 18/40 housekeeping genes with the lowest coefficients of variation (<0.6): AMMECR1L, CC2D1B ... cellular response to IL-1, cellular response to ...